16463061

Source:http://linkedlifedata.com/resource/pubmed/id/16463061

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0001792, umls-concept:C0015133, umls-concept:C0030705, umls-concept:C0079083, umls-concept:C0684249, umls-concept:C0920321
pubmed:issue	5
pubmed:dateCreated	2006-8-9
pubmed:abstractText	The combination of carboplatin and etoposide is currently considered the most appropriate regimen for treating elderly patients with small-cell lung cancer (SCLC). Previous reports on elderly patients, 70 years or older, found that the recommended dose was close to that of younger patients. Then, we conducted a phase I study of carboplatin and etoposide in elderly patients, 75 years or older, with SCLC. This study aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin, http://linkedlifedata.com/resource/pubmed/chemical/Creatinine, http://linkedlifedata.com/resource/pubmed/chemical/Etoposide
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0344-5704
pubmed:author	pubmed-author:DoiSeijiS, pubmed-author:FukudaMasaakiM, pubmed-author:FukudaMinoruM, pubmed-author:KasaiTakashiT, pubmed-author:KawabataShigeruS, pubmed-author:KinoshitaAkitoshiA, pubmed-author:KohnoShigeruS, pubmed-author:NagashimaSeijiS, pubmed-author:OkaMikioM, pubmed-author:SodaHiroshiH, pubmed-author:SoejimaYoshifumiY, pubmed-author:TakataniHiroshiH
pubmed:issnType	Print
pubmed:volume	58
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	601-6
pubmed:meshHeading	pubmed-meshheading:16463061-Aged, pubmed-meshheading:16463061-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16463061-Area Under Curve, pubmed-meshheading:16463061-Carboplatin, pubmed-meshheading:16463061-Carcinoma, Small Cell, pubmed-meshheading:16463061-Creatinine, pubmed-meshheading:16463061-Dose-Response Relationship, Drug, pubmed-meshheading:16463061-Drug Administration Schedule, pubmed-meshheading:16463061-Drug Eruptions, pubmed-meshheading:16463061-Etoposide, pubmed-meshheading:16463061-Female, pubmed-meshheading:16463061-Gastrointestinal Tract, pubmed-meshheading:16463061-Humans, pubmed-meshheading:16463061-Injections, Intravenous, pubmed-meshheading:16463061-Liver Function Tests, pubmed-meshheading:16463061-Lung Neoplasms, pubmed-meshheading:16463061-Male, pubmed-meshheading:16463061-Nausea, pubmed-meshheading:16463061-Neutropenia, pubmed-meshheading:16463061-Survival Analysis, pubmed-meshheading:16463061-Thrombocytopenia, pubmed-meshheading:16463061-Treatment Outcome, pubmed-meshheading:16463061-Vomiting
pubmed:year	2006
pubmed:articleTitle	A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
pubmed:affiliation	Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, and National Ureshino Hospital, Saga, Japan. mifukuda258@nifty.com
pubmed:publicationType	Journal Article, Clinical Trial, Phase I